President Donald Trump is facing pressure from U.S. hospitals and generic drugmakers to exempt medical goods from his new ...
Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...
Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
Cristina Brennan can hear the clock ticking. At the end of the year, her 12-year-old son Tristan will no longer have free ...
Investor's Business Daily on MSN21h
Amgen Shrugs Off A Surprise Setback For One Of Its Obesity DrugsAmgen stock rose early Wednesday, though the biotech behemoth said the FDA placed one of its obesity treatments on clinical ...
Hypercalcemia Treatment MarketThe global hypercalcemia treatment market is on track for significant growth, with an estimated valuation of USD 18.07 billion in 2023. The market is projected to expand ...
Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback